UBS Group
TEVA icon

UBS Group’s Teva Pharmaceuticals TEVA Stock Holding History

UBS Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.4M Buy
843,600
+776,700
+1,161% +$25M ﹤0.01% 2336
2025
Q4 		$2.09M Hold
66,900
– – ﹤0.01% 4941
2025
Q3 		$1.35M Sell
66,900
-70,900
-51% -$1.25M ﹤0.01% 5307
2025
Q2 		$2.31M Sell
137,800
-163,600
-54% -$2.64M ﹤0.01% 4661
2025
Q1 		$4.63M Buy
301,400
+234,500
+351% +$4.19M ﹤0.01% 3857
2024
Q4 		$1.47M Hold
66,900
– – ﹤0.01% 5004
2024
Q3 		$1.21M Sell
66,900
-38,400
-36% -$672K ﹤0.01% 4491
2024
Q2 		$1.71M Buy
105,300
+38,400
+57% +$591K ﹤0.01% 3926
2024
Q1 		$944K Buy
+66,900
New +$843K ﹤0.01% 4649
2023
Q2 		– Sell
-200,000
Closed -$1.77M – 9642
2023
Q1 		$1.77M Buy
200,000
+139,600
+231% +$1.38M ﹤0.01% 3560
2022
Q4 		$551K Hold
60,400
– – ﹤0.01% 4624
2022
Q3 		$487K Hold
60,400
– – ﹤0.01% 4365
2022
Q2 		$454K Buy
+60,400
New +$526K ﹤0.01% 4325
2022
Q1 		– Sell
-32,500
Closed -$260K – 10891
2021
Q4 		$260K Hold
32,500
– – ﹤0.01% 5476
2021
Q3 		$317K Hold
32,500
– – ﹤0.01% 5002
2021
Q2 		$322K Hold
32,500
– – ﹤0.01% 5035
2021
Q1 		$375K Sell
32,500
-445,700
-93% -$5.11M ﹤0.01% 5075
2020
Q4 		$4.62M Buy
+478,200
New +$4.58M ﹤0.01% 2528
2020
Q2 		– Sell
-216,900
Closed -$1.95M – 8348
2020
Q1 		$1.95M Buy
+216,900
New +$2.22M ﹤0.01% 2787
2019
Q4 		– Sell
-326,800
Closed -$2.25M – 8399
2019
Q3 		$2.25M Buy
326,800
+276,800
+554% +$2.12M ﹤0.01% 3177
2019
Q2 		$462K Sell
50,000
-332,100
-87% -$4M ﹤0.01% 4349
2019
Q1 		$5.99M Buy
382,100
+315,400
+473% +$5.56M ﹤0.01% 2069
2018
Q4 		$1.03M Sell
66,700
-18,000
-21% -$369K ﹤0.01% 3662
2018
Q3 		$1.82M Sell
84,700
-25,300
-23% -$587K ﹤0.01% 3298
2018
Q2 		$2.67M Sell
110,000
-16,000
-13% -$326K ﹤0.01% 2891
2018
Q1 		$2.15M Sell
126,000
-981,800
-89% -$19.2M ﹤0.01% 3079
2017
Q4 		$21M Buy
1,107,800
+622,500
+128% +$9.36M 0.01% 1171
2017
Q3 		$8.54M Sell
485,300
-33,110
-6% -$745K ﹤0.01% 1737
2017
Q2 		$17.2M Sell
518,410
-815,190
-61% -$25.2M 0.01% 1137
2017
Q1 		$42.8M Buy
1,333,600
+1,282,800
+2,525% +$43.8M 0.02% 610
2016
Q4 		$1.84M Sell
50,800
-1,100
-2% -$43.9K ﹤0.01% 2979
2016
Q3 		$2.39M Buy
+51,900
New +$2.71M ﹤0.01% 2685
2016
Q2 		– Sell
-165,000
Closed -$8.83M – 7966
2016
Q1 		$8.83M Sell
165,000
-245,500
-60% -$14.4M 0.01% 1418
2015
Q4 		$26.9M Hold
410,500
– – 0.02% 792
2015
Q3 		$23.2M Buy
410,500
+214,900
+110% +$13.9M 0.02% 806
2015
Q2 		$11.6M Sell
195,600
-10,600
-5% -$654K 0.01% 1363
2015
Q1 		$12.8M Sell
206,200
-2,845,800
-93% -$165M 0.01% 1271
2014
Q4 		$176M Buy
+3,052,000
New +$170M 0.12% 186

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's TEVA Position: Q1 2026 in Review

UBS Group reduced its Teva Pharmaceuticals (TEVA) stake by 56% in Q1 2026, selling an estimated $77.2M and leaving 1,877,217 shares worth $56.5M. The position accounts for 0.01% of the portfolio, ranked #1527.

UBS Group first reported a position in TEVA in Q4 2014 and has held it in 46 quarters since. The position peaked at $134M in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • UBS Group held 1,877,217 shares of Teva Pharmaceuticals worth $56.5M as of Q1 2026.
  • UBS Group sold 2,400,769 Teva Pharmaceuticals shares in Q1 2026, an estimated $77.2M.
  • Teva Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1527 holding.
  • UBS Group first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Teva Pharmaceuticals position peaked at $134M in Q4 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.